US Health – Leading You

US Health Group is located at 2,563 SW Grapevine Pkwy, Grapevine, TX 76051. It is one of America’s largest and most respected life insurance companies with a proud history dating back to November of 1959. Its founding was a movement of greater things to come.

One may find much information by visiting the company Crunchbase page. There, its Facebook, Twitter and LinkedIn page links are included as well as a link to the main website at www.UShealthfamily.com. Plus, an overview and description of the company are provided with a photo a few top contributors.

Helping other people every day, otherwise called HOPE, is not simply a clever acronym that describes US Health Advisors. It is far more as it encompasses its staff, contract agents, management and even its clients and partners as a greater whole. US Health Advisors has even made the news on BBB.org. According to Crunch Base’s timeline of the site, US Health Advisors has been in the business for nearly 60 years and is considered America’s choice for healthcare at its best.

Every social media link and recent update has also been posted to the Crunch Base contrabass page, where one may stay updated on all the new movements. After many years of dedicated work and faithful persistence by top-level executives, as well as mid to lower- level staff, US Health Advisors continues to fight to improve healthcare in reinventing solutions for the modern world. At US Health Advisors, there are plenty of opportunities to get one’s foot in the door and to earn a decent salary. Top salaries range from $78,000 to $200,000 per year and do not cap at that amount – for there’s always plenty of room for potential growth at US Health Advisors, where the sky’s the limit.

Account managers, insurance agents, sales specialists, licensed agents, hourly and monthly workers, sales managers, monthly contractors, seasonal tradesmen, licensed agents, field training managers, marketing executives, sales leaders, and several other well-paid positions are welcome. US Health Advisors constantly hiring and is always on the lookout for fresh talent. Training, advancement and placement opportunities abound.

One-Stop Shop With Beneful

It’s always great to find a brand whose product line includes everything you need. There’s so much less stress when your shopping doesn’t need to be spread out over multiple brand names, and everything comes from a source you trust.

For my puppy, that source is Beneful.

Most common around my house is Beneful’s dry food. There’s always a bag of Beneful IncrediBites under the kitchen counter for quick food bowl top-offs on my way out the door. If puppy is extra lucky (and I’m not running late) he might get a handful of shredded cheese or a scoop of wet dog food on top.

The wet food line, though, is a miracle all on its own. The Beneful Chopped Blends come in convenient, easy-open plastic packaging that’s great for travel. Whether puppy and I are going on a long trip together, or I’m sending him off to doggy daycare, it’s easy to toss a couple in a bag and not have to worry about his food. No mess and no smell!

But sometimes puppy gets anxious while we’re travelling, or bored when he’s at home, and that’s where Beneful Dental Twists come in. He can chew those things for hours! It keeps him out of trouble, and his teeth are one less thing for me to worry about! There’s even a noticeable improvement in his breath, which is invaluable for a dog so intent on giving kisses.

While the Dental Twists are great, they’re a little large to be ideal for things like obedience training, and last but not least, that brings us to Beneful Baked Delights. I know puppy doesn’t care what shape is treats are, but the little heart ones are so cute! They’re easy to conceal in a fist so that puppy can smell them but isn’t tempted to grab, and he’ll happily run through all his tricks if he gets one of those at the end.

All in all, Beneful is a brand that I trust, and is diverse enough that I’ve never had to look anywhere else.

Seattle Genetics founder Clay Siegall blazes new therapeutic trails

Clay Siegall attained his Ph.D in genetics in 1988 from George Washington University. He was quickly hired by the National Institutes of Health to manage one of their many cutting-edge cancer research programs. He stayed there from 1988 to 1991. He then took a job at Bristol-Meyers-Squibb, the pharmaceutical giant, as a senior researcher on their innovative line of chemotherapeutic agents. He continued this work until 1998.

 

Already with 10 years participating in the vanguard of modern cancer research, Dr. Siegall founded Seattle Genetics. His idea was not to compete with existing drug manufacturers’ approach to cancer treatment research. Instead, he would focus on novel means of fighting the disease, the then-nascent industry of targeted drug therapy. Remarkably, Siegall was able to secure tens of millions in venture capital before having produced even a single research paper. In 2001, he took the company public, raising an additional $50,000,000 in capital. This all took place years before Seattle Genetics had even its first drug approved for sale.

 

Over the 2000s, Siegall and his team of researchers worked feverishly, pursuing different strategies for fighting tumor genesis without the brutal, and sometimes lethal, secondary effects of metal-based chemotherapeutic agents. Finally, in 2009, Seattle Genetics completed its first phase I trial of its first patented drug, Brentuximab vedotin, marketed under the name Adcetris.

 

This would prove to be a game-changing drug in the fight against cancer. In 2011, Adcetris received FDA approval for use as a second-line treatment in Non-Hodgkin lymphoma. While this may sound like at best a modest achievement, this is the first antibody drug conjugate to be approved for cancer therapy in the United States. Dr. Siegall expects that as more phase II trials are completed, FDA approval will be extended to many other uses for the drug.

 

Under Siegall’s leadership, Seattle Genetics has also maintained at least 8 new drugs in the development pipeline. These are in every stage, from seeking patents to awaiting FDA approval. These drugs, which target tumor-specific proteins, hold the promise of replacing the existing chemotherapy regimens and making cancer treatment bearable for patients and their families. Clay Siegall has been and continues to be a leading figure in the fight against cancer.